Skip to main content

Measure Summaries In Progress

NQMC is currently working on 270 measures that have met the NQMC Inclusion Criteria. Measure titles, and their respective Measure Collections, are listed alphabetically by measure developer.

New reflects measures added to the NQMC work queue within the last 2 weeks.

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

Agency for Healthcare Research and Quality (2)

Agency for Healthcare Research and Quality (AHRQ) Quality Indicators

Esophageal resection mortality: percentage of in-hospital deaths per 1,000 discharges with esophageal resection for cancer, ages 18 years and older.

Pancreatic resection mortality: percentage of in-hospital deaths per 1,000 discharges with pancreatic resection, ages 18 years and older.

American Academy of Dermatology (3)

Melanoma II Physician Performance Measurement Set

Melanoma: percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

New Melanoma: percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within the 12 month period, into a recall system.

New Melanoma: percentage of patients, regardless of age, with a current diagnosis of Stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered.

American Medical Association (4)

AMA/PCPI Oncology Physician Performance Measurement Set

Oncology: percentage of female patients aged 18 years and older with Stage I (T1b) through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12 month reporting period.

Oncology: percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified.

Oncology: percentage of patients aged 18 through 80 years with American Joint Committee on Cancer (AJCC) Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12 month reporting period.

AMA/PCPI Prostate Cancer Performance Measurement Set

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

American Society for Radiation Oncology (1)

External Beam Radiotherapy for Bone Metastases

External beam radiotherapy (EBRT) for bone metastases: percentage of patients, regardless of age, with a diagnosis of bone metastases and no history of previous radiation who receive EBRT with an acceptable fractionation scheme as defined by the guideline.

American Society of Hematology (13)

Myelodysplastic Syndromes Measure Set

Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine.

Myelodysplastic syndromes (MDS): percentage of MDS patients for whom an established pathologic classification/risk prognostication system was used to help plan therapeutic options.

Myelodysplastic syndromes (MDS): percentage of MDS patients presenting with anemia who had a serum erythropoietin level less than or equal to 500 mU/ml prior to receiving erythropoietin/darbepoetin therapy.

Myelodysplastic syndromes (MDS): percentage of MDS patients presenting with anemia who had evidence of adequate iron stores within 60 days prior to receiving erythropoietin/darbepoetin therapy.

Myelodysplastic syndromes (MDS): percentage of MDS patients who are candidates for allogeneic stem cell transplant receiving irradiated transfusion products.

Myelodysplastic syndromes (MDS): percentage of MDS patients whose baseline diagnostic evaluation includes cytogenetic testing on bone marrow by standard karyotyping methods.

Myelodysplastic syndromes (MDS): percentage of patients with a diagnosis of MDS whose eligibility for a clinical trial was checked at least once a year.

Non-Hodgkin Lymphoma Measure Set

Non-Hodgkin lymphoma: percent of lymphoma patients advised to receive immunization/vaccination aligned with CDC recommendations.

Non-Hodgkin lymphoma: percent of lymphoma patients assigned a specific stage using Ann Arbor system including presence/absence of B symptoms AND having bone marrow biopsy or documentation why bone marrow biopsy was unnecessary or contraindicated.

Non-Hodgkin lymphoma: percent of lymphoma patients of childbearing age who received treatment for lymphoma and who were offered fertility counseling prior to starting treatment OR documentation in the medical record why such counseling was unnecessary.

Non-Hodgkin lymphoma: percent of lymphoma patients treated with anti-CD20 monoclonal antibody-containing regimens and tested for hepatitis B prior to medication administration.

Non-Hodgkin lymphoma: percent of lymphoma patients who are 65 years old or older and receiving CHOP +/-R, prescribed prophylactic myeloid growth factor (MGF).

Non-Hodgkin lymphoma: percent of patients with lymphoma whose initial lymphoma diagnosis was established by one of the following: incisional or excisional biopsy AND immunohistochemical characterization, OR core needle biopsy AND appropriate ancillary techniques employed.

C

Centers for Medicare & Medicaid Services (2)

Hospital Outpatient Department Quality Measures

Outpatient colonoscopy: facility level rate of risk-standardized, all-cause, unplanned hospital visits within 7 days of an outpatient colonoscopy.

National Hospital Inpatient Quality Measures

Sepsis: percentage of inpatients age 18 and over with a diagnosis of severe sepsis or septic shock who had the following performed, consistent with the Surviving Sepsis Campaign guidelines: measurement of lactate, obtaining blood cultures, administering broad spectrum antibiotics, fluid resuscitation, vasopressor administration, reassessment of volume status and tissue perfusion, and repeat lactate measurement.

M

MN Community Measurement (4)

Symptom Control during Chemotherapy

Symptom control during chemotherapy: percentage of chemotherapy patients 18 years of age and older for whom a symptom severity assessment was completed during days 5 to 15 of the chemotherapy cycle using the specified patient-reported outcome tool.

Symptom control during chemotherapy: percentage of chemotherapy patients 18 years of age and older whose constipation severity rating was none or mild during days 5 to 15 of the chemotherapy cycle.

Symptom control during chemotherapy: percentage of chemotherapy patients 18 years of age and older whose nausea severity rating was none or mild during days 5 to 15 of the chemotherapy cycle.

Symptom control during chemotherapy: percentage of chemotherapy patients 18 years of age and older whose pain severity rating was none or mild during days 5 to 15 of the chemotherapy cycle.

N

NHS Scotland (241)

Cancer Quality Performance Indicators (QPIs)

Acute leukaemia: proportion of patients with acute leukaemia 60 years of age and over receiving intensive chemotherapy who are enrolled in a clinical trial.

Acute leukaemia: proportion of patients with acute leukaemia 60 years of age and over with performance status (PS) 0-1 who receive intensive chemotherapy.

Acute leukaemia: proportion of patients with acute leukaemia being treated with curative intent who are enrolled in a clinical trial.

Acute leukaemia: proportion of patients with acute leukaemia being treated with non-curative intent who are enrolled in a clinical trial.

Acute leukaemia: proportion of patients with acute leukaemia eligible for transplant (i.e., over 16 years of age and under 65 years of age) being treated with curative intent who have a specimen sent to the lab for tissue typing at diagnosis.

Acute leukaemia: proportion of patients with acute leukaemia undergoing treatment with curative intent who die in first complete remission (CR), within 1 year of diagnosis.

Acute leukaemia: proportion of patients with acute leukaemia undergoing treatment with curative intent who have complete diagnostic panel undertaken.

Acute leukaemia: proportion of patients with acute leukaemia who are discussed at a multi-disciplinary team (MDT) meeting within 6 weeks of diagnosis.

Acute leukaemia: proportion of patients with acute leukaemia who have World Health Organisation (WHO) classification assigned and recorded (either by multi-disciplinary team [MDT] or reporting haematologist/haematopathologist).

Acute leukaemia: proportion of patients with acute lymphoblastic leukaemia (ALL) being treated with curative intent who die within 35 days of treatment.

Acute leukaemia: proportion of patients with acute lymphoblastic leukaemia (ALL), less than 25 years of age, undergoing treatment with curative intent who are assessed for the presence of minimal residual disease (MRD) marker.

Acute leukaemia: proportion of patients with acute myeloid leukaemia (AML) being treated with curative intent who die within 30 days of treatment.

Acute leukaemia: proportion of patients with acute myeloid leukaemia (AML) who are suitable only for treatment with non-curative intent who receive palliative chemotherapy with either low dose cytarabine or azacytidine.

Acute leukaemia: proportion of patients with acute promyelocytic leukaemia (APL) who receive all trans-retinoic acid (ATRA) within 1 day of diagnosis.

Bladder cancer: number of radical cystectomy procedures performed by a surgeon over a 1 year period.

Bladder cancer: proportion of patients with bladder cancer who receive treatment with curative intent (radical cystectomy, radiotherapy and chemotherapy) who die within 30 to 90 days of treatment.

Bladder cancer: proportion of patients with bladder cancer who undergo primary radical cystectomy where greater than or equal to 10 lymph nodes are resected and pathologically examined.

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) or cystectomy where pathology report contains all relevant data items.

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where a bladder diagram/detailed description with documentation of tumour location, size, number and appearance has been used at initial resection.

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where detrusor muscle is included in the specimen at initial resection.

Bladder cancer: proportion of patients with bladder cancer who undergo transurethral resection of bladder tumour (TURBT) where it is documented whether the resection was complete or not at initial resection.

Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) where detrusor muscle is absent from specimen, who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial TURBT.

Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) where initial resection is incomplete, who have a second resection or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial TURBT.

Bladder cancer: proportion of patients with high risk non muscle invasive bladder cancer (NMIBC) who have undergone transurethral resection of bladder tumour (TURBT) who have a second TURBT or early cystoscopy (± biopsy) within 6 weeks (42 days) of initial resection.

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who have neo-adjuvant chemotherapy who undergo cystectomy or chemoradiation within 8 weeks of treatment.

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who undergo radical cystectomy or radiotherapy only within 3 months of diagnosis of MIBC.

Bladder cancer: proportion of patients with muscle invasive bladder cancer (MIBC) who undergo radical surgery who met with an oncologist prior to radical cystectomy.

Bladder cancer: proportion of patients with non muscle invasive bladder cancer (NMIBC) who are discussed at the multidisciplinary team (MDT) meeting following initial transurethral resection of bladder tumour (TURBT).

Bladder cancer: proportion of patients with non muscle invasive bladder cancer (NMIBC) who undergo transurethral resection of bladder tumour (TURBT) who receive a single instillation of mitomycin C within 1 day of initial resection.

Bladder cancer: proportion of patients with transitional cell carcinoma of the bladder (T2-T4) receiving radical radiotherapy treated concomitantly with chemotherapy.

Brain and central nervous system (CNS) cancer: proportion of newly-diagnosed patients with brain/CNS cancer discussed at multidisciplinary team (MDT) meeting who have a documented World Health Organisation (WHO) performance status at the time of MDT discussion.

Brain and central nervous system (CNS) cancer: proportion of patients with a histological diagnosis of brain/CNS cancer where the histological pathology report contains a full set of data items.

Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer undergoing oncological treatment (chemotherapy or radiotherapy) who are managed by a specialist neuro-oncologist.

Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer undergoing surgical resection and/or radical radiotherapy or chemotherapy who receive a MRI prior to treatment.

Brain and central nervous system (CNS) cancer: proportion of patients with brain/CNS cancer who are discussed at multidisciplinary team (MDT) meeting before definitive management.

Brain and central nervous system (CNS) cancer: proportion of patients with glioblastomas undergoing surgery where tissue sample is assessed for the MGMT promoter hypermethylation status within 21 days of surgery.

Brain and central nervous system (CNS) cancer: proportion of patients with glioma with an oligodendroglial component undergoing surgery where tissue sample is tested for 1p/19q within 21 days of surgery.

Brain and central nervous system (CNS) cancer: proportion of patients with high grade glioma (World of Health Organisation [WHO] grades III and IV) undergoing surgery who commence their oncological treatment (chemotherapy, radiotherapy, or chemoradiotherapy) within 6 weeks of surgery.

Brain and central nervous system (CNS) cancer: proportion of patients with malignant glioma (with enhancing component on pre-operative imaging) undergoing surgery (biopsy and surgical resection) where greater than 90% reduction in tumour volume is achieved.

Brain and central nervous system (CNS) cancer: proportion of patients with malignant glioma (with enhancing component on pre-operative imaging) undergoing surgical resection where greater than 90% reduction in tumour volume is achieved.

Brain and central nervous system (CNS) cancer: proportion of patients with malignant glioma (with enhancing component on pre-operative imaging) undergoing surgical resection who receive MRI within 3 days (72 hours) of surgical resection.

Brain and central nervous system cancer: proportion of patients with brain/central nervous system (CNS) cancer presenting with seizures at diagnosis who are seen by a neurologist or a nurse with expertise in epilepsy management.

Brain and central nervous system cancer: proportion of patients with brain/central nervous system (CNS) cancer undergoing radical radiotherapy for whom the radiotherapy planning process includes MRI fusion.

New Breast cancer: proportion of patients undergoing wide excision and/or an axillary sampling procedure for breast cancer as day case surgery.

New Breast cancer: proportion of patients with breast cancer (invasive or ductal carcinoma in situ) having breast conservation surgery with final radial excision margins of less than 1 mm.

New Breast cancer: proportion of patients with breast cancer (invasive or in situ) having breast conservation surgery who undergo re-excision or mastectomy following initial breast surgery.

New Breast cancer: proportion of patients with breast cancer having conservation surgery who who receive radiotherapy to the breast.

New Breast cancer: proportion of patients with breast cancer under 30 years of age referred to a specialist clinic for genetic testing.

New Breast cancer: proportion of patients with breast cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New Breast cancer: proportion of patients with breast cancer who are enrolled in an interventional clinical trial or translational research.

New Breast cancer: proportion of patients with breast cancer who die within 30 days of chemotherapy treatment.

New Breast cancer: proportion of patients with breast cancer who undergo immediate breast reconstruction at the time of mastectomy.

New Breast cancer: proportion of patients with invasive breast cancer for whom the HER2 status (as detected by immunohistochemistry [IHC] and/or fluorescence in situ hybridization [FISH] analysis) is reported within 2 weeks of core biopsy.

New Breast cancer: proportion of patients with invasive breast cancer who have a greater than or equal to 5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy.

New Breast cancer: proportion of patients with invasive breast cancer who undergo assessment of the axilla by ultrasound before surgery.

New Breast cancer: proportion of patients with invasive breast cancer with suspicious morphology reported on ultrasound who undergo a fine needle aspiration (FNA)/core biopsy of the axilla before surgery.

New Breast cancer: proportion of patients with invasive or in-situ breast cancer who have a non-operative diagnosis (core biopsy/large volume biopsy).

New Breast cancer: proportion of patients with triple negative breast cancer under 40 years of age referred to a specialist clinic for genetic testing.

New Breast cancer: proportion of surgically treated patients with breast cancer less than 20 mm whole tumour size on histology (invasive plus in situ disease) treated by breast conservation therapy.

New Cancer patient experience: percentage of patients who responded whether they experienced excellent communication from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Communication Measurement Tool.

New Cancer patient experience: percentage of patients who responded whether they experienced excellent information provision from healthcare professionals throughout their cancer care on the Cancer Quality Performance Indicator (QPI) Information Measurement Tool.

New Cancer patient experience: percentage of patients who responded whether they have been enabled by healthcare professionals to share decisions about their care and treatment on the Cancer Quality Performance Indicator (QPI) Shared Decision Making Measurement Tool.

New Cervical cancer: proportion of patients with cervical cancer undergoing primary radical radiotherapy who have PET/CT imaging prior to starting treatment.

New Cervical cancer: proportion of patients with cervical cancer undergoing radical radiotherapy (external beam or brachytherapy) whose overall treatment time, from start to the end of treatment, is not more than 56 days.

New Cervical cancer: proportion of patients with cervical cancer undergoing radical radiotherapy who receive concurrent chemotherapy.

New Cervical cancer: proportion of patients with cervical cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New Cervical cancer: proportion of patients with cervical cancer who have an MRI of the pelvis performed prior to definitive treatment.

New Cervical cancer: proportion of patients with cervical cancer who undergo surgery where surgical margins are clear of tumour.

New Cervical cancer: proportion of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB1 cervical cancer who undergo radical hysterectomy.

Clinical trial access: proportion of patients with cancer who are enrolled in an interventional clinical trial or translational research.

New Colorectal cancer: proportion of patients between 50 and 74 years of age at diagnosis with Dukes C, or high risk Dukes B, colorectal cancer who undergo surgical resection who receive adjuvant chemotherapy.

New Colorectal cancer: proportion of patients who undergo surgical resection for colorectal cancer who return to theatre to deal with complications related to the index procedure (within 30 days of surgery).

New Colorectal cancer: proportion of patients with colon cancer who undergo CT chest, abdomen and pelvis before definitive treatment.

New Colorectal cancer: proportion of patients with colorectal cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New Colorectal cancer: proportion of patients with colorectal cancer who die within 30 or 90 days of chemotherapy or radiotherapy treatment with curative intent.

New Colorectal cancer: proportion of patients with colorectal cancer who die within 30 or 90 days of emergency or elective surgical resection.

New Colorectal cancer: proportion of patients with colorectal cancer who undergo a surgical procedure involving anastomosis of the colon having anastomotic leak requiring intervention (radiological or surgical).

New Colorectal cancer: proportion of patients with colorectal cancer who undergo curative surgical resection where greater than or equal to 12 lymph nodes are pathologically examined.

New Colorectal cancer: proportion of patients with colorectal cancer who undergo elective surgical resection which involves stoma creation who are seen and have their stoma site marked pre-operatively by a nurse with expertise in stoma care.

New Colorectal cancer: proportion of patients with colorectal cancer who undergo elective surgical resection who have the whole colon visualised by colonoscopy or CT colonography before surgery, unless the non-visualised segment of colon is to be removed.

New Colorectal cancer: proportion of patients with rectal cancer undergoing definitive treatment (chemoradiotherapy or surgical resection) who undergo CT chest, abdomen and pelvis and MRI pelvis before definitive treatment.

New Colorectal cancer: proportion of patients with rectal cancer who undergo a surgical procedure involving anastomosis of the rectum (including anterior resection with total mesorectal excision [TME]) having anastomotic leak requiring intervention (radiological or surgical).

New Colorectal cancer: proportion of patients with rectal cancer who undergo elective primary surgical resection or surgical resection following short course neo-adjuvant radiotherapy in which the circumferential margin is clear of tumour.

New Colorectal cancer: proportion of patients with rectal cancer who undergo elective surgical resection following neo-adjuvant long course radiotherapy or chemoradiotherapy in which the circumferential margin is clear of tumour.

New Colorectal cancer: proportion of patients with rectal cancer with threatened or involved circumferential resection margin (CRM) on preoperative MRI who receive long course neo-adjuvant chemoradiotherapy.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing clinical examination of relevant draining lymph node basins as part of clinical staging.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing diagnostic excision biopsy who undergo a wide local excision.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing groin block dissection who have been referred to a lymphoedema service.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing partial biopsy who undergo a wide local excision.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their partial biopsy.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma who have their diagnostic excision biopsy carried out by a skin cancer clinician.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items.

New Cutaneous melanoma cancer: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items.

New Cutaneous melanoma cancer: proportion of patients with stage III and IV cutaneous melanoma who undergo CT or positron emission tomography (PET) CT prior to completion lymphadenectomy.

New Cutaneous melanoma cancer: proportion of patients with unresectable stage III and IV cutaneous melanoma who undergo systemic anti cancer therapy (SACT).

New Cutaneous melanoma cancer: proportion of patients with unresectable stage III or IV cutaneous melanoma who have their BRAF status checked.

Endometrial cancer: proportion of patients with endometrial cancer undergoing definitive surgery who undergo laparoscopic surgery.

Endometrial cancer: proportion of patients with endometrial cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

Endometrial cancer: proportion of patients with endometrial cancer who have an MRI and/or CT scan of the abdomen and pelvis prior to first treatment.

Endometrial cancer: proportion of patients with endometrial cancer who undergo total hysterectomy and bilateral salpingo-oophorectomy (TH/BSO).

Endometrial cancer: proportion of patients with stage IB, grade 1 or 2, or stage IA, grade 3 endometrioid or mucinous endometrial cancer having adjuvant vaginal brachytherapy.

Endometrial cancer: proportion of patients with stage IV endometrial cancer receiving chemotherapy.

New Head and neck cancer: proportion of patients with head and neck cancer undergoing radiotherapy who receive intensity modulated radiotherapy (IMRT).

New Head and neck cancer: proportion of patients with head and neck cancer who are discussed at a multi-disciplinary team (MDT) meeting before definitive treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who die within 30 or 90 days of curative treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who have a cytological or histological diagnosis before treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who have extracapsular spread and/or final excision margins of less than 1 mm following surgical resection who receive chemoradiation.

New Head and neck cancer: proportion of patients with head and neck cancer who have oral assessment before initiation of treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who smoke who are referred to smoking cessation before first treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who undergo CT and/or MRI of the primary site and draining lymph nodes with CT of the chest before the initiation of treatment.

New Head and neck cancer: proportion of patients with head and neck cancer who undergo nutritional screening with the Malnutrition Universal Screening Tool (MUST) before first treatment.

New Head and neck cancer: proportion of patients with head and neck cancer with final excision margins of less than 1 mm after open surgical resection with curative intent.

New Head and neck cancer: proportion of patients with oral, pharyngeal or laryngeal cancer who are seen by a specialist speech and language therapist (SLT) before treatment.

New HepatoPancreatoBiliary (HBC) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.

New HepatoPancreatoBiliary (HBC) cancer: proportion of patients with hepatocellular carcinoma (HCC) who meet the current UK listing criteria for orthotopic liver transplantation who are referred to the Scottish Liver Transplant Unit (SLTU) for consideration of liver transplantation.

New HepatoPancreatoBiliary (HPB) cancer: Number of surgical resections for pancreatic, duodenal or distal biliary tract cancer performed by each surgeon/centre in a given year.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients undergoing resection for pancreatic cancer who receive adjuvant chemotherapy.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients who undergo resection for pancreatic, distal biliary tract or duodenal cancer.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) not undergoing treatment with curative intent (liver transplantation, resection or ablative therapies) who receive trans-arterial chemoembolisation (TACE) or approved systemic anti-cancer therapy (SACT).

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment with curative intent (liver transplant, resection, or ablation) who die within 90 days of definitive treatment.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with HPB cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or biliary tract cancer who undergo CT of the chest, abdomen and pelvis.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or distal biliary tract cancer undergoing non-surgical treatment who have a cytological or histological diagnosis.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or distal biliary tract cancer undergoing surgical resection who die within 30 and 90 days.

New HepatoPancreatoBiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or distal biliary tract cancer who undergo pancreatoduodenectomy where greater than or equal to 15 lymph nodes are resected and pathologically examined.

New Lung cancer: proportion of patients with a pathological diagnosis of non small cell lung cancer (NSCLC) who have a tumour subtype identified.

New Lung cancer: proportion of patients with a pathological diagnosis of stage IIIB or IV non small cell lung cancer (NSCLC) who have molecular profiling undertaken.

New Lung cancer: proportion of patients with limited stage (stage I to IIIB) small cell lung cancer (SCLC), performance status 0 or 1, who receive radiotherapy greater than or equal to 40Gy and concurrent or sequential platinum-based chemotherapy.

New Lung cancer: proportion of patients with lung cancer not undergoing surgery who receive radiotherapy (54Gy or greater) ± chemotherapy, or stereotactic ablative radiotherapy (SABR).

New Lung cancer: proportion of patients with lung cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

New Lung cancer: proportion of patients with lung cancer who are enrolled in an interventional clinical trial or translational research.

New Lung cancer: proportion of patients with lung cancer who have a pathological diagnosis (including following surgical resection).

New Lung cancer: proportion of patients with lung cancer who receive active treatment who die within 30 days of treatment.

New Lung cancer: proportion of patients with lung cancer who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who have a cytological/histological diagnosis prior to treatment.

New Lung cancer: proportion of patients with lung cancer who receive treatment with curative intent (surgery, radical radiotherapy or chemoradiotherapy) who die within 90 days of treatment.

New Lung cancer: proportion of patients with N2 disease who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo contrast enhanced CT or contrast enhanced MRI prior to start of treatment.

New Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) not undergoing surgery who receive systemic anti cancer therapy.

New Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) undergoing resection by lobectomy or pneumonectomy who have at least 1 node from at least 3 N2 stations sampled at time of resection or at previous mediastinoscopy.

New Lung cancer: proportion of patients with non small cell lung cancer (NSCLC) who undergo surgical resection.

New Lung cancer: proportion of patients with small cell lung cancer (SCLC) not undergoing treatment with curative intent who receive palliative chemotherapy.

New Lung cancer: proportion of patients with small cell lung cancer (SCLC) who receive chemotherapy ± radiotherapy.

New Lung cancer: proportion of patients with stage I lung cancer not undergoing surgery who receive stereotactic ablative radiotherapy (SABR).

New Lung cancer: proportion of patients with stage I to II (T1aN0 to T2bN1, or T3N0) non small cell lung cancer (NSCLC) who undergo surgical resection.

New Lung cancer: proportion of patients with stage IIIA non small cell lung cancer (NSCLC), with performance status 0-1, not undergoing surgery who receive radical radiotherapy greater than or equal to 54Gy and concurrent or sequential chemotherapy.

New Lung cancer: proportion of patients with stage IIIB or IV non small cell lung cancer (NSCLC), with performance status 0 to 2 not undergoing surgery that are epidermal growth factor receptor (EGFR) or ALK positive who receive biological therapy.

New Lung cancer: proportion of patients with with non small cell lung cancer (NSCLC) who receive curative treatment (radical radiotherapy, radical chemoradiotherapy or surgical resection) who undergo PET CT prior to start of treatment.

New Lymphoma: proportion of patients with Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL) undergoing treatment with curative intent who have MYC testing prior to treatment.

New Lymphoma: proportion of patients with classical Hodgkin lymphoma (CHL) undergoing treatment with curative intent who undergo PET CT prior to treatment and within 2 weeks of radiology request.

New Lymphoma: proportion of patients with classical Hodgkin lymphoma (CHL) undergoing treatment with curative intent who undergo PET CT prior to treatment.

New Lymphoma: proportion of patients with diffuse large B cell lymphoma (DLBCL) who are undergoing chemotherapy treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT at end of chemotherapy treatment.

New Lymphoma: proportion of patients with early stage (stage 1a or 2a) classical Hodgkin lymphoma (CHL) who receive combined modality treatment (chemotherapy and radiotherapy).

New Lymphoma: proportion of patients with follicular lymphoma and diffuse large B cell lymphoma (DLBCL) who receive chemotherapy in combination with rituximab.

New Lymphoma: proportion of patients with grade 3b follicular lymphoma who receive treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) chemotherapy.

New Lymphoma: proportion of patients with lymphoma undergoing rituximab based treatment who have hepatitis B, hepatitis C and HIV status checked prior to treatment.

New Lymphoma: proportion of patients with lymphoma undergoing treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT scanning prior to treatment and within 2 weeks of radiology request.

New Lymphoma: proportion of patients with lymphoma undergoing treatment with curative intent who undergo CT of chest, abdomen and pelvis or PET CT scanning prior to treatment.

New Lymphoma: proportion of patients with lymphoma who are discussed at a multidisciplinary team (MDT) meeting within 6 weeks of diagnosis.

New Lymphoma: proportion of patients with nodal, non-bulky stage 1a diffuse large B-cell lymphoma (DLBCL) who receive local radiotherapy, in combination with chemotherapy.

New Lymphoma: proportion of patients with primary cutaneous lymphoma who are discussed at a specialist multidisciplinary team (MDT) meeting.

Ovarian cancer: proportion of epithelial ovarian cancer patients who receive platinum-based chemotherapy, either in combination or as a single agent.

Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) who have less then 1 cm macroscopic residual disease following surgery.

Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) who have no macroscopic residual disease following surgery.

Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) undergoing delayed primary surgery following neo-adjuvant chemotherapy where optimal cytoreduction is achieved (residual disease less than 1 cm).

Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) undergoing delayed primary surgery following neo-adjuvant chemotherapy.

Ovarian cancer: proportion of patients with early stage epithelial ovarian cancer (FIGO Stage 1) undergoing primary surgery and operated on by a gynaecological oncologist, who have an adequate staging operation involving total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and washings.

Ovarian cancer: proportion of patients with early stage epithelial ovarian cancer (FIGO Stage 1) undergoing primary surgery who have an adequate staging operation involving total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and washings.

Ovarian cancer: proportion of patients with epithelial ovarian cancer having a CT scan or MRI of the abdomen and pelvis performed prior to starting definitive treatment.

Ovarian cancer: proportion of patients with epithelial ovarian cancer having a histo/cytological diagnosis recorded prior to starting neo-adjuvant chemotherapy with confirmation obtained by histology.

Ovarian cancer: proportion of patients with epithelial ovarian cancer having a histo/cytological diagnosis recorded prior to starting neo-adjuvant chemotherapy.

Ovarian cancer: proportion of patients with epithelial ovarian cancer undergoing pelvic clearance surgery having a complete pathology report as defined by the Royal College of Pathologists.

Ovarian cancer: proportion of patients with epithelial ovarian cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

Ovarian cancer: proportion of patients with Stage 1 epithelial ovarian cancer having Risk of Malignancy Index (RMI) assessed and recorded in their notes prior to any definitive surgical intervention.

New Prostate cancer: number of radical prostatectomy procedures performed by a surgeon over a 1 year period.

New Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy and docetaxel chemotherapy.

New Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy.

New Prostate cancer: proportion of patients with high risk prostate cancer undergoing radical treatment who have an MRI of the prostate and isotope bone scan (or alternative whole body MRI evaluation).

New Prostate cancer: proportion of patients with intermediate risk prostate cancer undergoing radical treatment who have an MRI of the prostate.

New Prostate cancer: proportion of patients with metastatic prostate cancer (TanyNanyM1) discussed at the multidisciplinary team (MDT) within 4 weeks of commencing treatment.

New Prostate cancer: proportion of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the multidisciplinary team (MDT) before definitive treatment.

New Prostate cancer: proportion of patients with pathologically confirmed, organ confined (stage pT2) prostate cancer who undergo radical prostatectomy in which tumour is present at the margin (i.e., positive surgical margin).

New Prostate cancer: proportion of patients with prostate adenocarcinoma who undergo prostate needle biopsy where the pathology report contains a full set of data items.

New Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo multiparametric MRI within 6 months of diagnosis.

New Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo trans-rectal ultrasound guided (TRUS) prostate re-biopsy within 14 months of diagnosis.

New Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 0 pads per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.

New Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 1 pad per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.

New Prostate cancer: proportion of patients with prostate cancer who are enrolled in an interventional clinical trial or translational research.

New Prostate cancer: proportion of patients with prostate cancer who die within 30 days of chemotherapy.

New Prostate cancer: proportion of patients with prostate cancer who undergo trans-rectal ultrasound guided (TRUS) biopsy of the prostate where a minimum of 10 cores are received by pathology.

Renal cancer: number of renal surgical resections performed by a surgeon over a 1 year period.

Renal cancer: proportion of patients diagnosed with renal cell carcinoma (RCC) who were clinically staged using TNM staging system before first treatment.

Renal cancer: proportion of patients presenting with advanced and/or metastatic renal cell carcinoma (RCC) who receive systemic anti-cancer therapy (SACT) for RCC within 12 months of diagnosis.

Renal cancer: proportion of patients who die within 30 or 90 days of treatment for renal cell carcinoma (RCC).

Renal cancer: proportion of patients with clear cell renal cell carcinoma (RCC) who are assigned a Leibovich score following radical nephremctomy.

Renal cancer: proportion of patients with metastatic renal cell carcinoma (RCC) who are assigned a valid prognostic score prior to commencing treatment.

Renal cancer: proportion of patients with renal cancer who are enrolled in an interventional clinical trial or translational research.

Renal cancer: proportion of patients with renal cell carcinoma (RCC) receiving active treatment who undergo cross-sectional imaging of the chest, abdomen +/- pelvis before first treatment.

Renal cancer: proportion of patients with renal cell carcinoma (RCC) undergoing cryotherapy or radiofrequency ablation as their first treatment who have a histological diagnosis (confirmed by biopsy) before commencing treatment.

Renal cancer: proportion of patients with renal cell carcinoma (RCC) undergoing systemic anti-cancer therapy (SACT) as their first treatment who have a histological diagnosis (confirmed by biopsy) before commencing treatment.

Renal cancer: proportion of patients with renal cell carcinoma (RCC) who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

Renal cancer: proportion of patients with T1a renal cell carcinoma (RCC) undergoing partial nephrectomy who achieve trifecta (warm ischaemia time less than 25 minutes, negative surgical margins and no complications).

Renal cancer: proportion of patients with T1aN0M0 renal cell carcinoma (RCC) who undergo nephron sparing surgery (NSS) (laparoscopic partial nephrectomy or open partial nephrectomy).

Sarcoma: proportion of patients with extremity sarcoma who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

Sarcoma: proportion of patients with extremity sarcoma who have a histological diagnosis before undergoing a planned surgical resection.

Sarcoma: proportion of patients with extremity sarcoma who undergo a primary limb-sparing surgery.

Sarcoma: proportion of patients with extremity sarcoma who undergo successful primary flap reconstruction following surgical resection.

Sarcoma: proportion of patients with extremity sarcoma who undergo surgical resection with curative intent where R0 resection is achieved.

Sarcoma: proportion of patients with extremity soft tissue sarcoma who are clinically staged using tumour node metastases (TNM) staging system prior to definitive treatment.

Sarcoma: proportion of patients with high or moderate risk gastrointestinal stromal tumour (GIST), small bowel GISTs and primary metastatic GIST who have mutational analysis within 3 months of diagnosis.

Sarcoma: proportion of patients with patients with Ewing’s sarcoma who are under the age of 50 who undergo neoadjuvant combination systemic anti-cancer therapy (SACT).

Sarcoma: proportion of patients with patients with osteosarcoma who are under the age of 40 who undergo neoadjuvant combination systemic anti-cancer therapy (SACT).

Sarcoma: proportion of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment.

Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment.

Sarcoma: proportion of patients, aged 16 years and over, with grade 2 or 3 deep extremity soft tissue sarcoma undergoing a planned marginal or wide local excision (R0 or R1) who commenced post-operative radiotherapy within 3 months of surgery.

Sarcoma: proportion of patients, aged 16 years and over, with high risk gastrointestinal stromal tumour (GIST) who commence adjuvant imatinib within 3 months of complete macroscopic resection.

New Testicular cancer: proportion of patients with metastatic testicular cancer undergoing systemic anti-cancer therapy (SACT) within 3 weeks of a multi-disciplinary team (MDT) decision to treat with SACT.

New Testicular cancer: proportion of patients with metastatic testicular cancer who have serum tumour markers (STMs) checked 2 weeks before starting chemotherapy.

New Testicular cancer: proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin area under the curve of 7 mg/ml/min (AUC7), based on ethylene diamine tetra-acetic acid (EDTA) clearance, within 8 weeks of orchidectomy.

New Testicular cancer: proportion of patients with stage I testicular non-seminomatous germ cell tumour (NSGCT) (or mixed) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.

New Testicular cancer: proportion of patients with testicular cancer undergoing orchidectomy where the histological pathology report contains tumour type and size, vascular invasion and rete stromal invasion (based upon the current Royal College of Pathologists dataset).

New Testicular cancer: proportion of patients with testicular cancer undergoing orchidectomy, who undergo pre-operative assessment of the testicle which, at a minimum, includes: (i) serum tumour markers (STMs), and (ii) testicular ultrasound.

New Testicular cancer: proportion of patients with testicular cancer undergoing primary orchidectomy within 2 weeks of ultrasonographic diagnosis.

New Testicular cancer: proportion of patients with testicular cancer who are discussed at a multi-disciplinary team (MDT) meeting to agree on a definitive management plan post orchidectomy.

New Testicular cancer: proportion of patients with testicular cancer who die within 30 days of treatment for testicular cancer.

New Testicular cancer: proportion of patients with testicular cancer who undergo computed tomography (CT) scanning of the chest, abdomen and pelvis within 3 weeks of orchidectomy.

New Upper gastrointestinal (GI) cancer: proportion of patients undergoing surgical resection for oesophageal or gastric cancer who are discharged within 21 days of surgical procedure.

New Upper gastrointestinal (GI) cancer: proportion of patients with gastric cancer who undergo surgical resection where greater than or equal to 15 lymph nodes are resected and pathologically examined.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who are discussed at the multi-disciplinary team (MDT) meeting before definitive treatment.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who are referred to a dietitian within 4 weeks of diagnosis.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who die within 30 or 90 days of surgical resection for oesophageal or gastric cancer.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who have a histological diagnosis made following initial endoscopy and biopsy.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who have tumour node metastases (TNM) stage and treatment intent recorded at a multi-disciplinary team (MDT) meeting prior to treatment.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive curative oncological treatment who die within 30 days of treatment.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive neo-adjuvant chemotherapy who then undergo surgical resection.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who receive palliative oncological treatment who die within 30 days of treatment.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo CT of the abdomen +/- chest +/- pelvis.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo curative treatment.

New Upper gastrointestinal (GI) cancer: proportion of patients with oesophageal or gastric cancer who undergo surgical resection in which circumferential and longitudinal surgical margin is clear of tumour (i.e., negative surgical margin).

About NQMC Measure Summaries

NQMC provides structured summaries containing information about measures and their development.

Submit Measures

Learn how to submit your evidence-based measures.

Measure Summary Archive

View list of summaries that have been withdrawn from NQMC.